N-(4,5-dimethylisoxazol-3-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide | 948573-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-(4,5-dimethylisoxazol-3-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide
• 英文别名: N-(4,5-dimethyl-1,2-oxazol-3-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide
• CAS: 948573-58-8
• 化学式: C₁₄H₁₆N₂O₄
• 分子量: 276.292
• InChiKey: FHKAMEHRICQXDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲氧基喹啉 、 N-(4,5-dimethylisoxazol-3-yl)-2-(4-hydroxy-2-methoxyphenyl)acetamide 在 4-二甲氨基吡啶 作用下， 以 氯苯 为溶剂， 反应 14.0h， 以60%的产率得到N-(4,5-dimethyl-1,2-oxazol-3-yl)-2-[2-methoxy-4-(6-methoxyquinolin-4-yl)oxyphenyl]acetamide
  参考文献：
  名称：

  Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

  摘要：

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.074

文献信息

• QUINOLINE DERIVATIVES
  申请人：Jung Frederic Henri

  公开号：US20090076074A1

  公开（公告）日：2009-03-19

  The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及公式I的喹啉衍生物或其药学上可接受的盐，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有在本说明书中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于治疗细胞增殖性疾病的药物的过程中的使用。
• US7973164B2
  申请人：——

  公开号：US7973164B2

  公开（公告）日：2011-07-05
• Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases
  作者：Patrick A. Plé、Frédéric Jung、Sue Ashton、Laurent Hennequin、Romuald Laine、Christine Lambert-van der Brempt、Rémy Morgentin、Georges Pasquet、Sian Taylor

  DOI：10.1016/j.bmcl.2012.03.074

  日期：2012.5

  A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.